These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 27777771)

  • 1. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors.
    Hall M; Liu H; Malafa M; Centeno B; Hodul PJ; Pimiento J; Pilon-Thomas S; Sarnaik AA
    J Immunother Cancer; 2016; 4():61. PubMed ID: 27777771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of tumor-infiltrating lymphocytes in breast cancer.
    Stanton SE; Disis ML
    J Immunother Cancer; 2016; 4():59. PubMed ID: 27777769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous tumour-specific cytotoxic T-cell clone established from tumour-infiltrating lymphocytes (TIL) of malignant ascites in the absence of recombinant interleukin 2(rIL2): activation by autologous tumour cell alone.
    Katano M; Nagumo F; Kubota E; Yamamoto H; Matsuo T; Hisatsugu T; Tadano J
    Biotherapy; 1993; 6(1):25-32. PubMed ID: 8507542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy.
    Kelderman S; Heemskerk B; Fanchi L; Philips D; Toebes M; Kvistborg P; van Buuren MM; van Rooij N; Michels S; Germeroth L; Haanen JB; Schumacher NM
    Eur J Immunol; 2016 Jun; 46(6):1351-60. PubMed ID: 27005018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Functional and phenotypic analysis of tumor infiltrating lymphocytes derived from solid tumors and effusion associated lymphocytes in malignant ascites cultured in recombinant interleukin 2].
    Itoh K; Shiiba K; Ebina N; Anzai R; Ouchi A; Matsuno S
    Nihon Geka Gakkai Zasshi; 1993 Aug; 94(8):781-90. PubMed ID: 8377752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
    Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
    J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Smith CV; Pecorelli S; Radominska-Pandya A; Cannon MJ; Parham GP
    Gynecol Obstet Invest; 2001; 51(4):254-61. PubMed ID: 11408737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype.
    Rivoltini L; Arienti F; Orazi A; Cefalo G; Gasparini M; Gambacorti-Passerini C; Fossati-Bellani F; Parmiani G
    Cancer Immunol Immunother; 1992; 34(4):241-51. PubMed ID: 1311218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.
    Chacon JA; Sarnaik AA; Chen JQ; Creasy C; Kale C; Robinson J; Weber J; Hwu P; Pilon-Thomas S; Radvanyi L
    Clin Cancer Res; 2015 Feb; 21(3):611-21. PubMed ID: 25472998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
    J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
    J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
    Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
    Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
    Chung YR; Kim HJ; Jang MH; Park SY
    Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer.
    Malone CC; Schiltz PM; Mackintosh AD; Beutel LD; Heinemann FS; Dillman RO
    Cancer Biother Radiopharm; 2001 Oct; 16(5):381-90. PubMed ID: 11776755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large scale expansion of human tumor infiltrating lymphocytes with surface-modified stimulator cells for adoptive immunotherapy.
    Chin Y; Janssens J; Smeyers E; Bleus J; Zhang J; Raus J
    Anticancer Res; 1992; 12(3):733-6. PubMed ID: 1622131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.
    Webb JR; Milne K; Nelson BH
    Cancer Immunol Res; 2015 Aug; 3(8):926-35. PubMed ID: 25957117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
    J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional analysis of TCR gamma delta+ T cells in tumour-infiltrating lymphocytes (TIL) of human pancreatic cancer.
    Kitayama J; Atomi Y; Nagawa H; Kuroda A; Mutoh T; Minami M; Juji T
    Clin Exp Immunol; 1993 Sep; 93(3):442-7. PubMed ID: 8370173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells.
    Kass R; Bellone S; Palmieri M; Canè S; Bignotti E; Henry-Tillman R; Hutchins L; Cannon MJ; Klimberg S; Santin AD
    Breast Cancer Res Treat; 2003 Aug; 80(3):275-85. PubMed ID: 14503800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor.
    Yoshino I; Yano T; Murata M; Ishida T; Sugimachi K; Kimura G; Nomoto K
    Cancer Res; 1992 Feb; 52(4):775-81. PubMed ID: 1737336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.